2형 당뇨병 치료 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the type 2 diabetes treatment market size is expected to grow from USD 52.60 billion in 2025 to USD 57.33 billion in 2026 and is forecast to reach USD 91.78 billion by 2031 at 9.87% CAGR over 2026-2031.

This report is Segmented by Drug Class (Biguanides, Sulfonylureas, Thiazolidinediones, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Insulin), Route of Administration (Oral, Injectable, Intravenous), Distribution Channel (Hospital, Retail, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Value (USD).

Global Type 2 Diabetes Treatment Market Trends and Insights

Rising Prevalence of Obesity-Linked Insulin Resistance

Obesity-linked insulin resistance is a core demand driver for the type 2 diabetes treatment market, because the condition is driving new diagnoses across both mature and emerging healthcare systems. A 2025 analysis in Frontiers in Public Health found that deaths from type 2 diabetes attributable to high BMI rose 203.9% between 1990 and 2021, while disability-adjusted life years increased at an annual rate of 8.9%. The International Diabetes Federation also projects that the global diabetes population will reach 853 million by 2050, which points to a long runway for treatment demand in the type 2 diabetes treatment market. The burden is rising fastest in middle-income countries, where underdiagnosis, undertreatment, and rising medicine costs increasingly interact with one another. A younger adult cohort is also becoming more important, because earlier onset of the disease extends lifetime exposure to therapy and broadens the need for long-term cardiometabolic management.

Rapid Uptake of GLP-1 Receptor Agonists

Rapid adoption of GLP-1 receptor agonists is changing the revenue mix of the type 2 diabetes treatment market, because these drugs are now valued for weight, cardiovascular, and glycemic outcomes together. In October 2025, the FDA approved oral semaglutide for cardiovascular risk reduction in high-risk adults with type 2 diabetes, making it the first oral GLP-1 receptor agonist with proven cardiovascular benefit. In May 2026, Novo Nordisk made Ozempic tablets available in the United States, and in April 2026 the FDA approved Eli Lilly's Foundayo, the first non-peptide oral GLP-1 therapy. These launches are widening the addressable patient base in the type 2 diabetes treatment market by reducing the hesitation linked to self-injection. They are also raising the strategic value of oral delivery, because premium incretin therapy is now moving deeper into a segment once led mainly by mature generic products.

High Cost of Novel GLP-1 and Smart Delivery Therapies

High prices for advanced GLP-1 products and smart insulin delivery systems continue to restrain the type 2 diabetes treatment market, even as clinical demand remains strong. The November 2025 U.S. pricing agreements lowered starter prices for some patients, but affordability gaps still remain for uninsured and underinsured groups. Closed-loop delivery systems add device spending on top of medicine costs, which limits adoption beyond higher-income patient groups in many countries. Payers also use step edits, therapy sequencing, and biosimilar pressure to contain spending, which can slow the use of premium treatments even when clinical need is clear. In practical terms, the type 2 diabetes treatment market is seeing strong innovation, but the premium end of the therapy stack still faces a meaningful affordability ceiling.

Other drivers and restraints analyzed in the detailed report include:

1. Cardiometabolic Label Expansion for Existing Therapies
2. Expansion of Continuous Glucose Monitoring Reimbursement
3. Reimbursement Friction in Step-Therapy and Prior Authorization

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

GLP-1 receptor agonists held 41.83% of the type 2 diabetes treatment market share in 2025, which kept them in the leading position across drug classes. Their lead was supported by long-running cardiovascular data and by newer label expansions that moved them closer to first-line use in high-risk patient groups. The 2025 and 2026 regulatory cycle also reduced the oral delivery gap, with oral semaglutide gaining a wider cardiovascular role and Foundayo entering the market as the first non-peptide oral GLP-1 therapy. In the type 2 diabetes industry, this shifts the class from a specialist premium option toward a broader mainstream therapy set. Biguanides, led by metformin generics, still keep a large clinical footprint because they remain cheap, familiar, and widely tolerated in first-line treatment pathways.

SGLT2 inhibitors are projected to grow at 10.09% CAGR from 2026 to 2031, which makes them the fastest-growing drug class in the type 2 diabetes treatment market. Their growth is tied to rising use in heart failure and kidney disease, not just blood sugar control, and a 2026 meta-analysis confirmed lower all-cause mortality and heart failure hospitalization across trial data. China also added momentum in January 2026, when Olorigliflozin Capsules received NMPA approval, pointing to stronger domestic competition in the class. DPP-4 inhibitors still retain relevance in cost-sensitive settings such as Japan and India, although they face slower long-term positioning than SGLT2 and GLP-1 therapies. Sulfonylureas and thiazolidinediones continue to lose relative appeal, while insulin remains necessary in advanced cases but faces volume pressure in higher-income markets where newer options are moving earlier in the care pathway.

Complete Report Scope:

• By Drug Class
  • Biguanides
  • Sulfonylureas
  • Thiazolidinediones
  • DPP-4 Inhibitors
  • GLP-1 Receptor Agonists
  • SGLT2 Inhibitors
  • Insulin
  • Others by Drug Class
• By Route of Administration
  • Oral
  • Injectable
  • Intravenous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 39.91% of type 2 diabetes treatment market share in 2025, which made it the largest regional contributor. The region benefits from high treatment intensity, broad familiarity with premium therapies, and faster uptake of GLP-1 receptor agonists and SGLT2 inhibitors than most other markets. Reimbursement for continuous glucose monitoring is also widening, with public and private coverage changes improving access and data visibility across care pathways. Faster review pathways also support the region, as the FDA approved Foundayo under the National Priority Voucher program in 50 days during April 2026. Canada and Mexico add meaningful demand, although tighter formulary controls in both countries can slow premium therapy penetration relative to the United States.

Europe holds a substantial position in the type 2 diabetes treatment market because major countries maintain structured reimbursement systems and established chronic care pathways. Germany, the United Kingdom, France, Italy, and Spain continue to anchor demand for cardioprotective therapies and premium branded products. In September 2025, oral semaglutide gained an expanded cardiovascular label in Europe, which strengthened the role of oral GLP-1 treatment across the region. Europe is also relevant for connected care models, as companies continue to use digital support programs to strengthen treatment engagement and persistence. Lower-income parts of the region benefit from wider access to insulin and related therapies as biosimilar availability improves.

Asia-Pacific is projected to grow at 13.34% CAGR through 2031, which makes it the fastest-growing regional block in the type 2 diabetes treatment market. The region combines large patient pools with accelerating regulatory activity, especially in China and India . China approved differentiated therapies such as ecnoglutide in January 2026 and Olorigliflozin in the same month, which shows a stronger domestic innovation cycle across both GLP-1 and SGLT2 pathways. India remains important because of its scale, rising metabolic burden, and increasing adoption of newer therapies in urban care settings. Japan, South Korea, and Australia support premium-price volumes, while the Middle East and Africa and South America remain smaller contributors but continue to gain from improving access and rising chronic disease treatment needs.

1. Abbott Laboratories
2. Astellas Pharma
3. AstraZeneca
4. Beckton Dickinson
5. Biocon
6. Boehringer Ingelheim
7. Dexcom
8. Eli Lilly and Company
9. Insulet
10. Johnson & Johnson
11. Medtronic
12. Merck
13. MicroPort
14. Novartis
15. Novo Nordisk
16. Pfizer
17. Roche
18. Sanofi
19. Takeda Pharmaceuticals
20. Tandem Diabetes Care
21. Ypsomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Obesity-Linked Insulin Resistance
  • 4.2.2 Rapid Uptake of GLP-1 Receptor Agonists
  • 4.2.3 Expansion of Continuous Glucose Monitoring Reimbursement
  • 4.2.4 Pharma-Tech Partnerships for Connected Care
  • 4.2.5 Closed-Loop Insulin Delivery in Consumer Wearables
  • 4.2.6 Cardiometabolic Label Expansion for Existing Therapies
• 4.3 Market Restraints
  • 4.3.1 High Cost of Novel GLP-1 and Smart Delivery Therapies
  • 4.3.2 Reimbursement Friction in Step-Therapy and Prior Authorization
  • 4.3.3 Supply Constraints for Injectable Formats and Pen Components
  • 4.3.4 Connectivity, Cybersecurity, and Data-Privacy Burden on Connected Devices
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Drug Class
  • 5.1.1 Biguanides
  • 5.1.2 Sulfonylureas
  • 5.1.3 Thiazolidinediones
  • 5.1.4 DPP-4 Inhibitors
  • 5.1.5 GLP-1 Receptor Agonists
  • 5.1.6 SGLT2 Inhibitors
  • 5.1.7 Insulin
  • 5.1.8 Others by Drug Class
• 5.2 By Route of Administration
  • 5.2.1 Oral
  • 5.2.2 Injectable
  • 5.2.3 Intravenous
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies
  • 5.3.3 Online Pharmacies
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Astellas Pharma Inc.
  • 6.3.3 AstraZeneca plc
  • 6.3.4 Becton, Dickinson and Company
  • 6.3.5 Biocon Limited
  • 6.3.6 Boehringer Ingelheim International GmbH
  • 6.3.7 Dexcom, Inc.
  • 6.3.8 Eli Lilly and Company
  • 6.3.9 Insulet Corporation
  • 6.3.10 Johnson and Johnson
  • 6.3.11 Medtronic plc
  • 6.3.12 Merck and Co., Inc.
  • 6.3.13 MicroPort Scientific Corporation
  • 6.3.14 Novartis AG
  • 6.3.15 Novo Nordisk A/S
  • 6.3.16 Pfizer Inc.
  • 6.3.17 Roche Holding AG
  • 6.3.18 Sanofi
  • 6.3.19 Takeda Pharmaceutical Company Limited
  • 6.3.20 Tandem Diabetes Care, Inc.
  • 6.3.21 Ypsomed Holding AG

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment